“Targeting IL23p19 Using Risankizumab for the Management of Moderate-to-Severely Active Crohn’s Disease: The Next Frontier?” (2023) Canadian IBD Today, 1(S05), pp. 2–7. doi:10.58931/cibdt.2023.1S0510.